251 related articles for article (PubMed ID: 24442487)
1. Antiangiogenic therapy of brain tumors: the role of bevacizumab.
Trevisan E; Bertero L; Bosa C; Magistrello M; Pellerino A; Rudà R; Soffietti R
Neurol Sci; 2014 Apr; 35(4):507-14. PubMed ID: 24442487
[TBL] [Abstract][Full Text] [Related]
2. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapies for glioblastoma.
Arrillaga-Romany I; Norden AD
CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007
[TBL] [Abstract][Full Text] [Related]
4. Is there a Role for Bevacizumab in Non-Glial Tumors?
Trevisan E; Bertero L; Magistrello M; Rudà R; Soffietti R
Curr Drug Targets; 2015; 16(7):684-8. PubMed ID: 25808649
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
Goldlust SA; Cavaliere R; Newton HB; Hsu M; Deangelis LM; Batchelor TT; Gilbert MR; Lassman AB
J Neurooncol; 2012 Apr; 107(2):407-11. PubMed ID: 22203237
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
Castro BA; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E9. PubMed ID: 25581938
[TBL] [Abstract][Full Text] [Related]
8. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
12. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
13. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab therapy for glioblastoma: a passionate discussion.
Desjardins A; Friedman HS
CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
[No Abstract] [Full Text] [Related]
16. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
Carbonell WS; DeLay M; Jahangiri A; Park CC; Aghi MK
Cancer Res; 2013 May; 73(10):3145-54. PubMed ID: 23644530
[TBL] [Abstract][Full Text] [Related]
17. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
Stupp R; Weller M
Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
[No Abstract] [Full Text] [Related]
18. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for malignant gliomas.
Iwamoto FM; Fine HA
Arch Neurol; 2010 Mar; 67(3):285-8. PubMed ID: 20212225
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.
Hu YL; DeLay M; Jahangiri A; Molinaro AM; Rose SD; Carbonell WS; Aghi MK
Cancer Res; 2012 Apr; 72(7):1773-83. PubMed ID: 22447568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
